Evaluación de la incidencia de enfermedades criptogámicas foliares en cereales de invierno y primavera en España. Periodo 1993-1996.

El trabajo presenta los resultados de evaluar las micosis foliares de los cereales durante tres campañas de cultivo consecutivas: 1993-94; 1994-95 y 1995-96. En la campaña 1993-1994 fueron evaluadas 154 variedades de trigo, triticale y cebada. Durante 1994-1995 se valoraron 145 variedades. En 1995-1996 fueron 161 las prospectadas y se ampliaron las observaciones a 9 cultivares de avena. Las variedades estuvieron cultivadas en ocho toponimias cerealícolas de España. Los resultados pusieron de manifiesto que las enfermedades más importantes fueron: Septoria tritici, Blumeria graminis f.sp.tritici, Puccinia recondita f.sp.tritici y Pyrenophora teres, en trigo blando o harinero(primavera e invierno),trigo duro y triticale. Muy discreta fue la presencia de la roya amarilla (Puccinia striiformis f.sp.tritici). En cebada (primavera y verano), Pyrenophora teres, Rhynchosporium secalis y Blumeria graminis f.sp.hordei fueron las especies fúngicas más importantes. Para las variedades de avena fue Puccinia coronata (roya coronada la enfermedad más frecuente. No pudieron establecerse diferencias entre variedades por su resistencia a alguno de los patógenos encontrados

Pathogenicity and fusaric acid production by fusarium proliferatum isolated from garlic in Spain

Fusarium proliferatum has been reported on garlic in the north west U.S.A., Spain and Serbia, causing as water-soaked tan lesions on cloves. Moreover, F. proliferatum is known to produce a range of toxins, including fumonisin B1, moniliformin, beauvericin, fusaproliferin and fusaric acid, which are implicated in pathogenesis. In this study six randomly selected F. proliferatum isolates from garlic were tested for pathogenicity and screened for fusaric acid production. Healthy seedlings of onion (Allium cepa), leek (A. porrum) and chives (A. schoenoprasum) and garlic clones (A. sativum) were inoculated. Onion seedlings and garlic clones were soaked in the conidial suspensions of each F. proliferatum isolate for 24 h and then planted in flats containing soil previously inoculated with the same isolate of F. proliferatum. Plants were maintained in a temperature and light-controlled greenhouse (12 h/12 h light/dark; 25/21°C). The root and bulb/clove rot disease symptoms were graded into five classes following the method of Stankovick et al. (2007). A disease severity index (DSI) was calculated as the mean of three plants of each species and four test replicates. Symptoms on onion and garlic plants were observed three weeks after inoculation. The overall effects of isolate, host and variety were analyzed. Effects were significant for all the studied isolates. The correlations between isolate pathogenicity and production of FA are also discussed

Species of Fusarium isolated from river and sea water of Southeastern Spain and pathogenicity on four plant species

Species of Fusarium were isolated from water samples collected from the Andarax River and coastal sea water of the Mediterranean in Granada and Almería provinces of southeastern Spain. In total, 18 water samples were analyzed from the Andarax River, and 10 species of Fusarium were isolated: Fusarium anthophilum, F. acuminatum, F. chlamydosporum, F. culmorum, F. equiseti, F. verticillioides, F. oxysporum, F. proliferatum, F. solani, and F. solani. When considering the samples by their origins, 77.8% of the river water samples yielded at least one species of Fusarium , with F. oxysporum comprising 72.2% of the total isolates. In the case of marine water, 45.5% of the samples yielded at least one species of Fusarium, with F. solani comprising 36.3% of the total isolates. The pathogenicity of 41 isolates representing nine of the species collected from river an sea water during the study ws evluated on barley, kohlrabe, melon, and tomato. Inoculation with F. acuminatum, F. chlamydosporum, F. culmorum, F. equiseti, F. verticillioides, F. oxysporum, F. proliferatum F. solani, and F. sambucinum resulted in pre-and post-emergence damping off. Pathogenicity of Fusarium isolates did not seem to be related to the origin of the isolates (sea water or fresh water). However, the presence of pathogenic species of Fusarium in river water flowing to the sea could indicate long-distance dispersal in natural water environment

Evaluación del poder patógeno de especies de Fusarium aisladas de aguas de cauces fluviales y fondos marinos de España sobre cuatro especies vegetales.

En este artículo se estudia la patogenicidad de las especies de Fusarium aisladas de muestras de fondos marinos del Mediterráneo y de aguas del cauce del río Andarax en las provincias de Granada y Almería (Sureste de España) sobre plántulas de cebada, colirrábano, melón y tomate. La evaluación del poder patógeno se hizo para 41 aislados de 9 especies de Fusarium aisladas de agus de mar y de río: F. acuminatum, F. chlamydosporum, F.culmorum, F. equiseti, F. verticillioides, F. oxysporum, F. proliferatum, F. sambucinum y F. solani. Todos los aislados de las diferentes especies mostraron patogenicidad tanto en preemergencia como en postemergencia de plántulas. No fue posible distiguir a los aislados según su procedencia: aguas marinas o de río

Solar Neutrinos Before and After KamLAND

We use the recently reported KamLAND measurements on oscillations of reactor anti-neutrinos, together with the data of previously reported solar neutrino experiments, to show that: (1) the total 8B neutrino flux emitted by the Sun is 1.00(1.0 \pm 0.06) of the standard solar model (BP00) predicted flux, (2) the KamLAND measurements reduce the area of the globally allowed oscillation regions that must be explored in model fitting by six orders of magnitude in the Delta m^2-tan^2 theta plane, (3) LMA is now the unique oscillation solution to a CL of 4.7sigma, (4) maximal mixing is disfavored at 3.1 sigma, (5) active-sterile admixtures are constrained to sin^2 eta<0.13 at 1 sigma, (6) the observed ^8B flux that is in the form of sterile neutrinos is 0.00^{+0.09}_{-0.00} (1 sigma), of the standard solar model (BP00) predicted flux, and (7) non-standard solar models that were invented to completely avoid solar neutrino oscillations are excluded by KamLAND plus solar at 7.9 sigma . We also refine quantitative predictions for future 7Be and p-p solar neutrino experiments.Comment: Published version, includes editorial improvement

Robust signatures of solar neutrino oscillation solutions

With the goal of identifying signatures that select specific neutrino oscillation parameters, we test the robustness of global oscillation solutions that fit all the available solar and reactor experimental data. We use three global analysis strategies previously applied by different authors and also determine the sensitivity of the oscillation solutions to the critical nuclear fusion cross section, S_{17}(0), for the production of 8B. The favored solutions are LMA, LOW, and VAC in order of g.o.f. The neutral current to charged current ratio for SNO is predicted to be 3.5 +- 0.6 (1 sigma), which is separated from the no-oscillation value of 1.0 by much more than the expected experimental error. The predicted range of the day-night difference in charged current rates is (8.2 +- 5.2)% and is strongly correlated with the day-night effect for neutrino-electron scattering. A measurement by SNO of either a NC to CC ratio > 3.3 or a day-night difference > 10%, would favor a small region of the currently allowed LMA neutrino parameter space. The global oscillation solutions predict a 7Be neutrino-electron scattering rate in BOREXINO and KamLAND in the range 0.66 +- 0.04 of the BP00 standard solar model rate, a prediction which can be used to test both the solar model and the neutrino oscillation theory. Only the LOW solution predicts a large day-night effect(< 42%) in BOREXINO and KamLAND. For the KamLAND reactor experiment, the LMA solution predicts 0.44 of the standard model rate; we evaluate 1 sigma and 3 sigma uncertainties and the first and second moments of the energy spectrum.Comment: Included predictions for KamLAND reactor experiment and updated to include 1496 days of Super-Kamiokande observation

Diversity of Staphylococcus aureus Isolates in European Wildlife

Staphylococcus aureus is a well-known colonizer and cause of infection among animals and it has been described from numerous domestic and wild animal species. The aim of the present study was to investigate the molecular epidemiology of S. aureus in a convenience sample of European wildlife and to review what previously has been observed in the subject field. 124 S. aureus isolates were collected from wildlife in Germany, Austria and Sweden; they were characterized by DNA microarray hybridization and, for isolates with novel hybridization patterns, by multilocus sequence typing (MLST). The isolates were assigned to 29 clonal complexes and singleton sequence types (CC1, CC5, CC6, CC7, CC8, CC9, CC12, CC15, CC22, CC25, CC30, CC49, CC59, CC88, CC97, CC130, CC133, CC398, ST425, CC599, CC692, CC707, ST890, CC1956, ST2425, CC2671, ST2691, CC2767 and ST2963), some of which (ST2425, ST2691, ST2963) were not described previously. Resistance rates in wildlife strains were rather low and mecA-MRSA isolates were rare (n = 6). mecC-MRSA (n = 8) were identified from a fox, a fallow deer, hares and hedgehogs. The common cattle- associated lineages CC479 and CC705 were not detected in wildlife in the present study while, in contrast, a third common cattle lineage, CC97, was found to be common among cervids. No Staphylococcus argenteus or Staphylococcus schweitzeri-like isolates were found. Systematic studies are required to monitor the possible transmission of human- and livestock- associated S. aureus/MRSA to wildlife and vice versa as well as the possible transmission, by unprotected contact to animals. The prevalence of S. aureus/MRSA in wildlife as well as its population structures in different wildlife host species warrants further investigation

Why Are Outcomes Different for Registry Patients Enrolled Prospectively and Retrospectively? Insights from the Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF).

Background: Retrospective and prospective observational studies are designed to reflect real-world evidence on clinical practice, but can yield conflicting results. The GARFIELD-AF Registry includes both methods of enrolment and allows analysis of differences in patient characteristics and outcomes that may result. Methods and Results: Patients with atrial fibrillation (AF) and ≥1 risk factor for stroke at diagnosis of AF were recruited either retrospectively (n = 5069) or prospectively (n = 5501) from 19 countries and then followed prospectively. The retrospectively enrolled cohort comprised patients with established AF (for a least 6, and up to 24 months before enrolment), who were identified retrospectively (and baseline and partial follow-up data were collected from the emedical records) and then followed prospectively between 0-18 months (such that the total time of follow-up was 24 months; data collection Dec-2009 and Oct-2010). In the prospectively enrolled cohort, patients with newly diagnosed AF (≤6 weeks after diagnosis) were recruited between Mar-2010 and Oct-2011 and were followed for 24 months after enrolment. Differences between the cohorts were observed in clinical characteristics, including type of AF, stroke prevention strategies, and event rates. More patients in the retrospectively identified cohort received vitamin K antagonists (62.1% vs. 53.2%) and fewer received non-vitamin K oral anticoagulants (1.8% vs . 4.2%). All-cause mortality rates per 100 person-years during the prospective follow-up (starting the first study visit up to 1 year) were significantly lower in the retrospective than prospectively identified cohort (3.04 [95% CI 2.51 to 3.67] vs . 4.05 [95% CI 3.53 to 4.63]; p = 0.016). Conclusions: Interpretations of data from registries that aim to evaluate the characteristics and outcomes of patients with AF must take account of differences in registry design and the impact of recall bias and survivorship bias that is incurred with retrospective enrolment. Clinical Trial Registration: - URL: http://www.clinicaltrials.gov . Unique identifier for GARFIELD-AF (NCT01090362)

Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry.

BACKGROUND: The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is an ongoing prospective noninterventional registry, which is providing important information on the baseline characteristics, treatment patterns, and 1-year outcomes in patients with newly diagnosed non-valvular atrial fibrillation (NVAF). This report describes data from Indian patients recruited in this registry. METHODS AND RESULTS: A total of 52,014 patients with newly diagnosed AF were enrolled globally; of these, 1388 patients were recruited from 26 sites within India (2012-2016). In India, the mean age was 65.8 years at diagnosis of NVAF. Hypertension was the most prevalent risk factor for AF, present in 68.5% of patients from India and in 76.3% of patients globally (P < 0.001). Diabetes and coronary artery disease (CAD) were prevalent in 36.2% and 28.1% of patients as compared with global prevalence of 22.2% and 21.6%, respectively (P < 0.001 for both). Antiplatelet therapy was the most common antithrombotic treatment in India. With increasing stroke risk, however, patients were more likely to receive oral anticoagulant therapy [mainly vitamin K antagonist (VKA)], but average international normalized ratio (INR) was lower among Indian patients [median INR value 1.6 (interquartile range {IQR}: 1.3-2.3) versus 2.3 (IQR 1.8-2.8) (P < 0.001)]. Compared with other countries, patients from India had markedly higher rates of all-cause mortality [7.68 per 100 person-years (95% confidence interval 6.32-9.35) vs 4.34 (4.16-4.53), P < 0.0001], while rates of stroke/systemic embolism and major bleeding were lower after 1 year of follow-up. CONCLUSION: Compared to previously published registries from India, the GARFIELD-AF registry describes clinical profiles and outcomes in Indian patients with AF of a different etiology. The registry data show that compared to the rest of the world, Indian AF patients are younger in age and have more diabetes and CAD. Patients with a higher stroke risk are more likely to receive anticoagulation therapy with VKA but are underdosed compared with the global average in the GARFIELD-AF. CLINICAL TRIAL REGISTRATION-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362